COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs And Tests
Executive Summary
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
You may also be interested in...
Will The COVID-19 Pandemic Shake Up Access To Medicines?
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Countries Consider Pandemic Pooling of Rights And Compulsory Licensing
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.